ENTAENANTA PHARMACEUTICALS INCvs its industry peers
A metric-by-metric comparison of ENANTA PHARMACEUTICALS INC against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENTAThis | $358M#3 | — | 3.5x#4 | 5.5x#1 | -3.4%#1 | 29.4%#1 | -130.7%#1 | -81.0%#4 | — | — | — | — |
| BNTC | $389M#1 | — | 2.2x#3 | — | -100.0%#2 | -20.1%#3 | — | -25.7%#2 | — | — | -18.2%#3 | — |
| RCKT | $375M#2 | — | 1.0x#1 | — | — | 13.8%#2 | — | -60.5%#3 | — | — | 5.1%#2 | — |
| CTNM | $319M#4 | — | 1.3x#2 | — | -100.0%#2 | -41.9%#4 | — | -25.0%#1 | — | — | 16.8%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice